Cargando…

Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer

BACKGROUND: Human epidermal growth receptor 2-positive (HER2+) breast cancer (BC) is a heterogeneous subgroup. Estrogen receptor (ER) status is emerging as a predictive marker within HER2+ BCs, with the HER2+/ER+ cases usually having better survival in the first 5 years after diagnosis but have high...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Qian, Huang, Shujun, Desautels, Danielle, McManus, Kirk J., Murphy, Leigh, Hu, Pingzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Research Network of Computational and Structural Biotechnology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196919/ https://www.ncbi.nlm.nih.gov/pubmed/37216014 http://dx.doi.org/10.1016/j.csbj.2023.05.002

Ejemplares similares

Genes and functions from breast cancer signatures
por: Huang, Shujun, et al.
Publicado: (2018)

Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2(+):ERα(-) breast cancer
por: Liu, Jeffrey C., et al.
Publicado: (2017)

Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients
por: Mazo, Claudia, et al.
Publicado: (2020)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2− breast cancer: a retrospective cohort study
por: Xie, Yiqun, et al.
Publicado: (2022)

A Tumor initiating cell-enriched prognostic signature for HER2(+):ERα(−) breast cancer; rationale, new features, controversies and future directions
por: Liu, Jeff C., et al.
Publicado: (2013)

Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer
por: Liu, Yanqing, et al.
Publicado: (2022)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

Predicting the risk of acute kidney injury in primary care: derivation and validation of STRATIFY-AKI
por: Koshiaris, Constantinos, et al.
Publicado: (2023)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

Recurrent copy number alterations in young women with breast cancer
por: Chi, Chen, et al.
Publicado: (2018)

Computational Prediction of the Pathogenic Status of Cancer-Specific Somatic Variants
por: Feizi, Nikta, et al.
Publicado: (2022)

The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer
por: Fujiwara, Saori, et al.
Publicado: (2014)

Altona Prognostic Index: A New Prognostic Index for ER-Positive and Her2-Negative Breast Cancer of No Special Type
por: Wegscheider, Anne-Sophie, et al.
Publicado: (2021)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

Construction and validation of an immunity-related prognostic signature for breast cancer
por: Zhu, Tao, et al.
Publicado: (2020)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

Validation of a Proteomic Signature of Lung Cancer Risk from Bronchial Specimens of Risk-Stratified Individuals
por: Rahman, S.M. Jamshedur, et al.
Publicado: (2023)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Reply to Letter to Editor: “HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?”
por: Li, Shuai, et al.
Publicado: (2020)

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer
por: Ragusi, Max AA, et al.
Publicado: (2021)

Realising stratified psychiatry using multidimensional signatures and trajectories
por: Joyce, Dan W., et al.
Publicado: (2017)

Distinct interferon signatures stratify inflammatory and dysimmune myopathies
por: Rigolet, Muriel, et al.
Publicado: (2019)

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application
por: Laas, Enora, et al.
Publicado: (2016)

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures
por: Cockburn, Jessica G., et al.
Publicado: (2016)

Digital Validation of Breast Biomarkers (ER, PR, AR and HER2) in Cytology Specimens Using Three Different Scanners
por: Salama, Abeer M., et al.
Publicado: (2021)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis
por: Ethier, Josee-Lyne, et al.
Publicado: (2017)

A Comparative Study of the Use of Stratified Cross-Validation and Distribution-Balanced Stratified Cross-Validation in Imbalanced Learning
por: Szeghalmy, Szilvia, et al.
Publicado: (2023)

A Transcription Factor Signature Can Identify the CMS4 Subtype and Stratify the Prognostic Risk of Colorectal Cancer
por: Zhong, Min-Er, et al.
Publicado: (2022)

Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia
por: Li, Jun, et al.
Publicado: (2022)

Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
por: Rokavec, Matjaz, et al.
Publicado: (2023)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer
por: Ihnen, M, et al.
Publicado: (2010)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status
por: Zhao, Xi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_05u70rlvbh358uaq4hrt7r9p8t